Research & Development: Page 31
-
Q&A
'Nobel Prize of pharma' helps put Huma's digital health platform on the global map
The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.
By Kim Ribbink • June 23, 2022 -
Podcast
Woman of the Week: Kronos Bio's Barbara Kosacz
Deal-maker, mentor and biotech industry mover and shaker, the COO and general counsel brings her 'smiling tiger' skills to her new role at the emerging company.
By Taren Grom • June 21, 2022 -
Explore the Trendline➔
Getty ImagesTrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
#DIA2022: How the industry's top regulator views the future of healthcare
In the evolution of healthcare, data is the linchpin to making drug development more efficient.
By Michael Gibney • June 21, 2022 -
Q&A // Biotech Spotlight
Biotech spotlight: Karuna Therapeutics’ mission to rejuvenate the field of neuroscience
An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.
By Kim Ribbink • June 16, 2022 -
A patient-funded ALS drug offers hope where few treatments exist
Eledon Pharmaceuticals’ grassroots-backed drug recently entered clinical trials.
By Kelly Bilodeau • June 15, 2022 -
Profile
Buoyed by COVID-19 shot, J&J's vaccines head sees a new golden age approaching
Janssen’s goal to have ‘a vaccine for the world’ is part of what drew Penny Heaton to the company and its work.
By Alexandra Pecci • June 14, 2022 -
Q&A
Why biomanufacturing is the next innovation frontier for genomic therapies
While cell and gene therapy research has accelerated quickly, manufacturing in the space hasn’t quite kept up, Danaher’s Chief Science Officer JC Gutiérrez-Ramos says.
By Meagan Parrish • June 13, 2022 -
Q&A // First 90 Days
First 90 Days: Editas Medicine’s Gilmore O’Neill
The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.
By Michael Gibney • June 13, 2022 -
Q&A
A combo of precision meds and diagnostics could disrupt mental healthcare
HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.
By Kelly Bilodeau • June 8, 2022 -
Podcast
Woman of the Week: Janssen’s Najat Khan
Janssen’s Najat Khan, Ph.D., chief data science officer and global head of strategy and operations, shares how the company is using next-gen tech to ‘reimagine’ medicine.
By Taren Grom • June 8, 2022 -
Profile
After losing her daughter to a rare disease, Sharon King is looking to rewrite the playbook of drug development
The communications pro is lending her community-building, storytelling expertise to the Bespoke Gene Therapy Consortium.
By Alexandra Pecci • June 7, 2022 -
Pharma giants take on Appalachian cancer rates in newest screening initiative
AstraZeneca and Bristol Myers Squibb are teaming up with the nonprofit Association of Community Cancer Centers to increase lung cancer screening in rural Appalachia for the long haul.
By Karissa Waddick • June 7, 2022 -
Q&A // First 90 Days
First 90 Days: Janssen Immunology’s David Jimenez
The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.
By Taren Grom • June 6, 2022 -
How to build a cancer pipeline: Big Pharma oncology heads on driving science forward
Executives leading the cancer departments at J&J, Merck and Takeda chime in on what it takes to construct a successful and sustainable oncology drug pipeline.
By Michael Gibney • June 6, 2022 -
Profile
Flagship's creative approach to finding the next big idea in biopharma
Avak Kahvejian, partner at Flagship Pioneering, a company that conceives, creates and launches bioplatform companies like Moderna, discusses its latest venture, ProFound Therapeutics.
By Alexandra Pecci • June 1, 2022 -
Cell and gene therapy advances coming fast and furious
A peek into R&D at the Mass General Brigham network reveals up-and-coming treatments pushing the boundaries of what’s possible in medicine.
By Kelly Bilodeau • June 1, 2022 -
Q&A // First 90 Days
First 90 Days: Sosei Heptares’ Chris Cargill
The company’s new CEO is looking to drive growth through collaboration and transparency.
By Kim Ribbink • May 31, 2022 -
Podcast
Woman of the Week: Ferring Pharmaceutical's Araz Raoof
Growing up in Iraqi Kurdistan, Raoof says a 'lethal combination' of books and strong women paved her way into STEM.
By Taren Grom • May 25, 2022 -
Q&A // First 90 Days
First 90 Days: Syneos Health’s Michelle Keefe
The newly minted CEO is leaning on her 30 years of experience leading high-performance teams to make her mark at Syneos.
By Taren Grom • May 23, 2022 -
Retrieved from Diego Camargo/PharmaVoice on May 17, 2022
Podcast
Woman of the Week: Sparrow Pharmaceuticals' Jamie MacPherson
The vice president of regulatory affairs and quality on embracing leadership challenges in drug development.
By Taren Grom • May 18, 2022 -
Profile
Jumping into pharma with big plans at a small company
SpringWorks Therapeutics' chief medical officer on the ambition that drives him and his company to develop treatments for cancer patients.
By Alexandra Pecci • May 17, 2022 -
Q&A
BriOri BioTech sets the stage for the comeback of Vioxx
With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.
By Kelly Bilodeau • May 17, 2022 -
Q&A // Biotech Spotlight
Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach
Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.
By Michael Gibney • May 17, 2022 -
Are digital DCTs the answer for rare diseases?
How data from EHRs is helping to identify, diagnose and recruit patients to decentralized clinical trials.
By Kim Ribbink • May 16, 2022 -
After 40 years, researchers discover new frontiers in the fight against HIV
Medical advances in the last two decades may now provide scientists with the right toolbox to target the long-elusive virus.
By Karissa Waddick • May 16, 2022